What is Pfizer's eliquis — revenues:?

Pfizer (PFE) reported eliquis — revenues: of $2.17B in Q1 2026.

How has Pfizer's eliquis — revenues: changed year-over-year?

Pfizer's eliquis — revenues: increased by 12.6% year-over-year, from $1.92B to $2.17B.

What is the long-term trend for Pfizer's eliquis — revenues:?

Over 4 years (2021 to 2025), Pfizer's eliquis — revenues: has grown at a 7.5% compound annual growth rate (CAGR), from $5.97B to $7.96B.

What does eliquis — revenues: mean?

This metric represents the total gross sales generated by a specific pharmaceutical product line within the company's cardiovascular portfolio. It reflects the market demand, pricing power, and adoption rates of the drug among healthcare providers and patients globally. Monitoring this revenue stream is critical for assessing the product's lifecycle performance and its contribution to the company's overall top-line growth.

Pfizer PFE Eliquis — Revenues:

Other product segments

Prevnar Family

$1.69B+1.8%

Vyndaqel family

$1.6B+7.8%

Ibrance

$1.01B+3.2%

All Other Hospital and Biosimilars

$953M—

All other Primary Care

$654M+7.4%

Padcev

$591M+38.7%

All other Specialty Care

$579M+19.1%

Xtandi

$444M-3.1%

Oncology Biosimilars

$409M+54.9%

Royalty

$396M+28.6%

All other Oncology

$376M-0.3%

Nurtec ODT/Vydura

$353M+42.3%

Lorbrena

$305M+37.4%

Pfizer CentreOne

$289M+5.9%

Comirnaty

$232M-58.9%

Paxlovid

$219M-69.9%

Inlyta

$214M-2.3%

Sulperazon (Outside the U.S. and Canada)

$199M+21.3%

Adcetris

$190M-12.8%

Inflectra

$182M—

Abrysvo

$180M+37.4%

Xeljanz

$180M+40.6%

Braftovi/Mektovi

$174M+27.9%

Zavicefta (Outside the U.S. and Canada)

$150M+11.1%

Enbrel (Outside the U.S. and Canada)

$138M-1.4%

Bosulif

$129M-14.6%

Octagam

$122M—

Tukysa

$122M+19.6%

Zithromax

$112M-29.1%

Orgovyx

$109M—

Genotropin

$93M—

FSME-IMMUN/TicoVac

$81M—

Elrexfio

$80M+33.3%

Cibinqo

$76M+31.0%

Talzenna

$50M+25.0%

Tivdak

$33M0.0%

Similar metrics at other companies

BMYEliquis — Total Revenues

$4.14B+16.0%

SUPNQelbree — Total revenues

$77.84M+20.2%

JNJXarelto — Sales to customers (Note 9)

$642M-7.0%

TBPHYupelri Monotherapy — Revenue

$21.85M+7.0%

ABBVQulipta — Net revenues

$296M+53.4%

BMYEliquis — Percentage of reimbursement for development costs from alliance partner

60%0.0pp

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.21B-3.7%

Enterprise value$200.88B-1.3%

P/E11.4×—

P/S2.2×-0.1×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's eliquis — revenues:.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's eliquis — revenues:?: Pfizer (PFE) reported eliquis — revenues: of $2.17B in Q1 2026.
How has Pfizer's eliquis — revenues: changed year-over-year?: Pfizer's eliquis — revenues: increased by 12.6% year-over-year, from $1.92B to $2.17B.
What is the long-term trend for Pfizer's eliquis — revenues:?: Over 4 years (2021 to 2025), Pfizer's eliquis — revenues: has grown at a 7.5% compound annual growth rate (CAGR), from $5.97B to $7.96B.
What does eliquis — revenues: mean?: This metric represents the total gross sales generated by a specific pharmaceutical product line within the company's cardiovascular portfolio. It reflects the market demand, pricing power, and adoption rates of the drug among healthcare providers and patients globally. Monitoring this revenue stream is critical for assessing the product's lifecycle performance and its contribution to the company's overall top-line growth.